Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Any sales of the
Company's securities pursuant to this confidential document are intended to be in compliance with Regulation S of the US Securities Act of 1933, as amended (the "Act"). It cannot
therefore be made available to "US persons" within the meaning of rule 902(k) of the Act. No shares will be sold to US persons as defined above or to any person resident in the
United States.
https://www.mymetics.com/files/5015/3606/2025/180831_Mymetics_Company_Overview_-_website.pdf
Mymetics Corporation
www.mymetics.com › files › 5015/3606/2025
therefore be made available to "US persons" within the meaning of rule 902(k) of the Act. No shares will be sold to US persons as defined above or to any person resident in the United States.
Leads me to this!!
https://www.mymetics.com/files/5015/3606/2025/180831_Mymetics_Company_Overview_-_website.pdf
How to Produce Electricity from Cow Dung
https://www.wikihow.com/Produce-Electricity-from-Cow-Dung
EDGAR Pro
yahoo.brand.edgar-online.com › DisplayFilingInfo
and Thomas Staehelin as Directors ... Muller and Hansjorg Wyss 8 Ratify Auditors For For Management ..
Wanger Advisors Trust
4 Reelect Joachim Hausser, Willy Kissling, For For Management
Klaus-Michael Kuehne, Georg Obermeier,
and Thomas Staehelin as Directors
6 Receive the Report on Dividend Approved For For Management
by the Board of Directors
7 Elect Directors David Helfet, Andre For For Management
Muller and Hansjorg Wyss
https://yahoo.brand.edgar-online.com/DisplayFilingInfo.aspx?Type=HTML&text=%2526lt%253bNEAR%252f4%2526gt%253b(%22MICHAEL%22%2c%22BLACKBURN%22)&FilingID=4633012&ppu=%2fPeopleFilingResults.aspx%3fPersonID%3d2955629%26PersonName%3dMICHAEL%2520BLACKBURN
Delivering insulin in a pill
Technique could replace daily injections for diabetics
Wyss Institute for Biologically Inspired Engineering at Harvard.
By encapsulating the insulin-ionic liquid formulation in an enteric coating, the team overcame the first obstacle, resisting breakdown by gastric acids in the gut.
This study shows remarkable results where insulin given by mouth in combination with an ionic liquid works about as well as a conventional injection. The implications of this work to medicine could be huge, if the findings can be translated into pills that safely and effectively administer insulin and other peptide drugs to humans.”
https://www.seas.harvard.edu/news/2018/06/delivering-insulin-pill
Largest Cleft Charity | Medical Advisory Board | Smile Train
www.smiletrain.org › team › medical-advisory-board
Baylor College of Medicine Texas Children’s Hospital. Karoon Agrawal, MD. ... Hansjorg Wyss Department of Plastic Surgery New York University Langone Medical Center.
Roberto L. Flores, MD
Joseph G. McCarthy Associate Professor of Reconstructive Plastic Surgery
Director Cleft Lip and Palate
Director Craniofacial Surgery Fellowship
Hansjorg Wyss Department of Plastic Surgery
New York University Langone Medical Center
Larry Hollier Jr., MD, FACS
Chairman
Professor of Plastic Surgery
Baylor College of Medicine
Texas Children’s Hospital
https://www.smiletrain.org/team/medical-advisory-board
The Hansjörg Wyss Wellness Center Is Now Open at Bok
www.phillymag.com › healthcare-news › 2021/04/29
Apr 29, 2021 · The Hansjörg Wyss Wellness Center is composed of 12 examination rooms, with Altshuler, Deffler, and a newly hired nurse practitioner currently providing clinical care.
https://www.phillymag.com/healthcare-news/2021/04/29/hansjorg-wyss-wellness-center-bok-building/
Advisory Board Chair
John Markels, President Vaccines, Merck
John H. Markels, Ph.D., President, Merck Vaccines
John became President of Global Vaccines at Merck in 2019. Merck holds a $7 billion vaccines business and is a global leader providing a broad portfolio of pediatric, adolescent, and adult vaccines to the world. John brings greater than 30 years of pharmaceutical experience to this role. Immediately preceding this appointment, John was Merck's President for Latin America.
This Guy was on Maria Elena Bottazzi Linkedin page 4 days ago!!!
World Vaccine Congress
• 3rd+
R & D + Strategic partnering for the global vaccine industry #WVCW #WVCEU #WVCWC
4d • Edited • 4 days ago
Live now Moderator: Maria Elena Bottazzi Baylor College of Medicine, John Markels, Ph.D. Merck, Melanie Saville CEPI (Coalition for Epidemic Preparedness Innovations), David C. Kaslow, M.D. PATH, Prashant Yadav Harvard Medical School, Jonathan D. Quick Duke Global Health Institute "Is the current vaccine business response to emerging infectious diseases unsustainable?" panel on the final day of the World Vaccine Congress.
Join for free: https://buff.ly/3eVkS87
Organize the yearly NIH Site Visit and the External Scientific Advisory Board (ESAB) meeting in the Washington, D.C. area, as well as individual visits between Drs. Ruprecht, Villinger, Santangelo and Fleury. 7. Address intellectual property (IP) issues fairly, timely, and equitably.
https://reporter.nih.gov/search/dECpjLDvPk6PQQQ4WMiExA/project-details/10158410#similar-Projects
very nice find!! BRO!!
Good ole Barney Graham
Compared to flu and HIV, this is going to be relatively easy to accomplish.
Barney Graham, National Institute of Allergy and Infectious Diseases.
https://www.sciencemag.org/news/2021/04/vaccines-can-protect-against-many-coronaviruses-could-prevent-another-pandemic
UpToDate
www.uptodate.com › contents › respiratory-syncytial
Barney S Graham, MD, PhD Deputy Director Viral Pathogenesis Research ... Baylor College of Medicine Gregory Redding, MD Section Editor — Pediatric Pulmonology
https://www.uptodate.com/contents/respiratory-syncytial-virus-infection-clinical-features-and-diagnosis/contributors
Program at a Glance | Grand Challenges Forum COVID19 ...
grand-challenges.embs.org › 2020covid › program-at-a
Nov 12, 2020 · • Barney S. Graham, MD, Ph.D., NIAID Vaccine Research Center “Rapid Development of COVID-19 Vaccines” • Maria Elena Bottazzi, Ph.D., Baylor College of Medicine and Texas Children’s Hospital “COVID-19 Vaccines: Ensuring their Success for Global Access” • Bali Pulendran, Ph.D., Stanford School of Medicine
Symposium #4: Grand Challenges in COVID-19 Treatment 10:00 am – 1:30 pm EST
Moderator: Shankar Subramaniam
• Hanneke Schuitemaker, Ph.D., Johnson & Johnson
“Janssen’s efforts in the development of a COVID-19 vaccine”
• Barney S. Graham, MD, Ph.D., NIAID Vaccine Research Center
“Rapid Development of COVID-19 Vaccines”
• Maria Elena Bottazzi, Ph.D., Baylor College of Medicine and Texas Children’s Hospital
“COVID-19 Vaccines: Ensuring their Success for Global Access”
• Bali Pulendran, Ph.D., Stanford School of Medicine
“Systems immunology of COVID-19 infection and vaccination“
• Liang Schweizer, Ph.D., HiFiBiO Therapeutics
“Development of an Effective Neutralizing Antibody to Treat COVID 19”
• Neil King, Ph.D., University of Washington
“Computational design of two-component nanoparticle vaccines”
• Beth Jaworski, Ph.D., U.S. Department of Veterans Affairs
“COVID Coach: Digital Strategies for Addressing the Mental Health Impacts of COVID-19”
https://grand-challenges.embs.org/2020covid/program-at-a-glance/
Wow this go's way back!!
The authors thank Dr Toon Stegmann (Toulouse, France) for help in designing the membrane fusion assay, Dr C. Wayne Smith (Baylor College of Medicine, Houston, TX) and Dr Gabriel Lopez-Berestein (MD Anderson Cancer Center, Houston, TX) for helpful discussions, and Dr Raul Tonda (current address, Hospital Clinic, Barcelona, Spain) for assistance with the figures.
https://ashpublications.org/blood/article/106/5/1604/21488/Tissue-factor-bearing-microvesicles-arise-from
Coronavirus: Vaccines & Variants with Vin Gupta, MD, and Peter Hotez, MD, PhD
Vin Gupta, MD, MPA, MSc, is an Affiliate Assistant Professor of Health Metrics Sciences at the Institute for Health Metrics and Evaluation (IHME) at the University of Washington.
https://www.washingtonpost.com/washington-post-live/2021/05/10/coronavirus-vaccines-variants-with-vin-gupta-md-peter-hotez-md-phd/
Seems that never get's updated!!
Susan Banbury, PhD
Head of Formulation, Zydis Product Development
Catalent
Simon A Lawton, MD
Vice President, Global Medical Affairs
ALK
Adina Dîrlea, MSc
Senior Formulation Scientist, Formulation Development
Catalent
Charli Smardon, MSc
Formulation Scientist, New Product Development
Catalent ( HIV PATENT WITH MYMETICS)
https://event.on24.com/eventRegistration/EventLobbyServlet?target=reg20.jsp&partnerref=MJHSOCIAL&eventid=3100840&sessionid=1&key=74FC0E6C947513419C9146089153FF64®Tag=&V2=false&sourcepage=register
CATALENT
Is My Molecule Suitable for an Orally Disintegrating Tablet?
A panel of four speakers will review the fundamentals of ODTs, including benefits, formats and development pathways, contrast with other oral dose forms, outline likely drug candidates and discuss Catalent’s proprietary ZYDIS® lyophilized ODT platform. The panel will further address the unique delivery routes associated with ODTs, including the potential for pre-gastric or gastrointestinal delivery and local activity at the oral mucosa, and review the physicochemical characteristics appropriate for each.
https://www.catalent.com/expert-content/oral-technologies/is-my-molecule-suitable-for-an-orally-disintegrating-tablet/
2021 2021 UNIVERSITY OF LOUISIANA AT LAFAYETTE 799451273 LAFAYETTE LA 93.855 Allergy and Infectious Diseases Research 001 4 5/5/2021 NON-COMPETING CONTINUATION $1,719,534
https://taggs.hhs.gov/Detail/AwardDetail?arg_AwardNum=U19AI142636&arg_ProgOfficeCode=104
Here's from that Tolly's patent you posted!
University of Groningen Reconstituted viral envelopes as ...
research.rug.nl › files › 2766781
expression in mammalian cells failed, since long strands of dsRNA induce the synthesis of type I interferones. These cytokines lead to a general down-regulation of protein synthesis which ultimately results in apoptosis [8]. However, small stretches of dsRNA (< 30 bp) are well tolerated by cells and efficiently and selectively down-
https://pure.rug.nl/ws/portalfiles/portal/2766781/c4.pdf
Peripherally Administered Nanoparticles Target Monocytic Myeloid Cells, Secondary Lymphoid Organs and Tumors in Mice
Iraklis C. Kourtis, Sachiko Hirosue, Alexandre de Titta, Stephan Kontos, Toon Stegmann, Jeffrey A. Hubbell, Melody A. Swartz
https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0061646
Peripherally Administered Nanoparticles Target Monocytic Myeloid Cells, Secondary Lymphoid Organs and Tumors in Mice
Toon Stegmann
Jeffrey A. Hubbell
Melody A. Swartz
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=159097713
Poly(I:C) is a synthetic double-stranded RNA, which can be used as the core genetic material of the virosome and induce innate immunity by stimulating Toll-like receptor 3 (TLR3) pathway.[43] This inhalable nanovaccine can get into alveolar macrophages (AMs) and alveolar epithelial cells (AECs) with the help of surfactant proteins A (SP-A) and D (SP-D) without damaging the pulmonary surfactant to induce mucosal immunity
Mymetics Corporation (MYMX): Inhalable nanovaccine with ...
investorshub.advfn.com › boards › read_msg
Apr 18, 2021 · Poly(I:C) is a synthetic double-stranded RNA, which can be used as the core genetic material of the virosome and induce innate immunity by stimulating Toll-like receptor 3 (TLR3) pathway.[43]
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=163268499
https://europepmc.org/article/PMC/PMC7972832#figures-and-tables
poly(I:C)?=?polyinosinic:polycytidylic acid.
Overview - MyMetics
www.mymetics.com › files › 9314/4293/5168
Capside/RNA removed 2 OEG or DCPC removed 3 Starting Material: Influenza virus as starting material OR Other enveloped virus (i.e. HSV, RSV, CMV, etc) Lipid Viral membrane protein Add antigens +/-Adjuvant Solubilization (OEG or DCPC) 1 Creating Virosomes RNA Chimeric Virosome Homologous Virosome Reconstituted viral membrane = Virosome Natural
https://www.mymetics.com/files/9314/4293/5168/September_2015_Mymetics_Company_Overview_-_website.pdf
Transvac 2
The virosome-based vaccine induces potent humoral and cellular immune responses critical in confronting life-threatening viral diseases. While RNA viruses mutate at high rates, virosomes can be versatile carriers that could develop multi-antigen epitopes against all strains of RNA viruses.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=163346998
https://www.news-medical.net/news/20210420/Could-virosome-based-nanovaccines-be-a-promising-new-approach-to-preventing-viral-diseases.aspx
Tollys
Funds will further development of a new cancer immunotherapy: synthetic TLR3 agonist TL-532
https://www.life-sciences-france.com/news/tollys-closes-series-financing-andrew-lloyd-associates-ala-2001-116843.html
https://tollys.fr/tlr3-science/
Tollys’ lead candidate drug is a double-stranded RNA molecule that activates a protein called toll-like receptor 3 (TLR3), which is found on the surface of tumor cells.
When activated, TLR3 kills cancer cells and puts innate immune cells such as dendritic cells on high alert. The immune system is then trained by antigens from dead cancer cells to kill the cancer cells that weren’t destroyed by the drug and prevent regrowth of the tumor via a vaccination-type mechanism.
https://www.diwou.com/2020/05/28/french-startup-secures-e2-3m-to-advance-cancer-rna-immunotherapy/
Poly(I:C) is a synthetic double-stranded RNA, which can be used as the core genetic material of the virosome and induce innate immunity by stimulating Toll-like receptor 3 (TLR3) pathway.
https://https://europepmc.org/article/PMC/PMC7972832#figures-and-tablesinvestorshub.advfn.com/boards/read_msg.aspx?message_id=163268499
Efficacy and safety of an intranasal virosomal respiratory ...
www.researchgate.net › publication › 236053994
Poly(I:C) is a synthetic double-stranded RNA (dsRNA) molecule that induces effective mucosal immune responses by stimulating Toll-like receptor 3 (TLR3) as a molecular mimic of dsRNA, which is a ...
University of Groningen A virosomal respiratory syncytial ...
research.rug.nl › files › 2419204
Mymetics BV Leiden, The Netherlands ... Virosome technology 21 ... (TLRs), such as TLR3 and TLR4,18 underlining the role of this protein in immune evasion.
https://pure.rug.nl/ws/portalfiles/portal/2419204/PhD_thesis_Kamphuis_Pages_corr_1.pdf
Production and Characterization of Synthetic ErbB2 Virosomes for Vaccination Against Breast Cancer
Wyss Institute
at wyss.harvard.edu
https://scholar.google.com/citations?user=LxyxBzQAAAAJ&hl=en
Production and Characterization of Synthetic ErbB2 Virosomes for Vaccination Against Breast Cancer
https://dash.harvard.edu/handle/1/37799763
ovalbumin (OVA)
https://pubmed.ncbi.nlm.nih.gov/28214610/
Role of the Adiponectin Binding Protein, T-Cadherin (Cdh13 ...
dash.harvard.edu › bitstream › handle
bideficient mice to ovalbumin (OVA) and challenged the mice with aerosolized OVA or PBS. Compared to WT, T-cad 2/ mice were protected against OVA-induced airway hyperresponsiveness, increases in BAL inflammatory cells, and induction of IL-13, IL-17, and eotaxin expression.
https://dash.harvard.edu/bitstream/handle/1/10461895/3398886.pdf?sequence=1
Wyss Academy
Prof. Dr. Christian Leumann
President of the Board and Rector of the University of Bern
https://www.wyssacademy.org/board
Mayo Clinic / Clinical Trials (3) Liposomes / Cancer
https://www.mayoclinic.org/search/search-results?q=liposomes&topics=Clinical%20Trials
That" the million dolla ? WHO! IMO Who ever did / or will, will buyout MYMX
That Asset is worth one hell alot of money! Revolutionize Allergy/ Asthma!
That's a good ? my friend! All we know right now is that Beltrami Consulting ( Vanya Beltrami ) from Anergis SA has it!!
Jasper Bos
Senior Vice President & Managing Director at M Ventures
5d • 5 days ago
Yesterday marked the last day of my employment at M Ventures, as I will leave in order to start my next adventure soon.
It is with gratitude that I am closing the chapter of my career at Merck, and I am grateful to you all for the past 12 years of having had the privilege to work with you, learn from you and collaborate on so many exciting projects. I will be leaving with the feeling that Merck is a truly unique company which really empowers its employees to develop and take initiative, and values innovation above anything. I have always hugely valued the sense of trust and empowerment at Merck that that made sure that no single day at Merck was ever the same!
To everyone I worked with, either in our businesses, within M Ventures, within our portfolio companies, a really big thank you for an unforgettable past 12-years!
I will soon announce my next role, and am looking forward to continue to work with you to support innovative founders and venture backed companies in their mission to develop the best cures for patients with high unmet medical need .
All the best,
Jasper
Linkedlin
Klaus Schollmeier
Professional Board Member and Advisor to the Pharma/Biotech and Life Science Industry
Experience
Chemovator GmbH
EiR: External management advisor and venture team coach
Company Name Chemovator GmbH
Dates Employed Jul 2018 – Present
Employment Duration2 yrs 11 mos
Location Mannheim, Germany
https://www.chemovator.com/team/klaus-schollmeier/
Chemovator GmbH
The protected space for BASF intrapreneurs
https://www.chemovator.com/
Chemovator is the internal business incubator of BASF. Twelve early-stage ventures at a time can join our two-year full-time program in Mannheim.
Along the Chemovator Journey, we support our ventures with unconventional resources to validate their ideas around chemistry. With the help of a startup mindset, we enable our ventures to turn ideas into investable and scalable business opportunities.
Dr. Ramona Businger – Post Doc Analytical Development of ...
de.linkedin.com › in › dr-ramona-businger-40ab82171
We characterized GP-mediated virosome formation and delineated the role of the antiviral factor tetherin (BST2, CD317) in this process. Residues in the EBOV-GP receptor-binding domain (RBD) promote GP-virosome secretion, while tetherin suppresses GP-virosomes by interactions involving the GP-transmembrane domain.
Location: Tübingen, Baden-Württemberg, Deuts
Dr. Ramona Businger
Post Doc Analytical Development of Oncolytic Viruses bei Boehringer Ingelheim
Tübingen, Baden-Württemberg, Germany
Post Doc Analytical Development of Oncolytic Viruses
Company Name Boehringer Ingelheim Full-time
Dates Employed Nov 2020 – Present
Employment Duration7 mos
Location Biberach, Baden-Württemberg, Deutschland
Universität sklinikum Tübingen
Company Name Universität sklinikum Tübingen
Total Duration6 yrs 6 mos
Title Postdoctoral Research Fellow
Dates Employed May 2018 – Oct 2020
Employment Duration2 yrs 6 mos
Title Doktorandin
Dates Employed May 2014 – May 2018
Employment Duration4 yrs 1 mo
Location Tübingen und Umgebung, Deutschland
PhD Thesis:
"Subversion of Immune Cells by HCMV and HIV-1"
12.02.2019
Viral decoys - how the Ebola virus leads the immune system astray
(Ebola Virosome)
https://uni-tuebingen.de/en/university/news-and-publications/press-releases/archive/archivfullview-press-releases/article/viral-decoys-how-the-ebola-virus-leads-the-immune-system-astray/
Marketbeat says that WHEN IS MYMETICS' NEXT EARNINGS DATE?
Mymetics is scheduled to release its next quarterly earnings announcement on Friday, May 21st 2021.
View our earnings forecast for Mymetics.
https://www.marketbeat.com/stocks/OTCMKTS/MYMX/
NO MORE " Sound Of Silence " KEMPER'S LET'S HERE IT!!
Where Oh Where is MR KEMPER'S / ARE YOU GONE / SPEAK UP /
https://video.search.yahoo.com/yhs/search;_ylt=AwrWjWLU75JgxVkA3wsPxQt.;_ylu=Y29sbwNncTEEcG9zAzEEdnRpZAMEc2VjA3Nj?p=where+oh+where+are+you+tonight&type=frontier_pc_homerun_portal&hsimp=yhs-frontier1&hspart=frontier&ei=UTF-8&fr=yhs-frontier-frontier1#id=14&vid=7c596143dd602c53dff3cca14a44dbfd&action=view
Catalent Partners with Humanigen to Support FDA-Approved Phase 3 Lenzilumab Study for COVID-19
SOMERSET, N.J. – May 7, 2020
https://www.clinical.catalent.com/catalent-news/catalent-to-support-humanigen-lenzilumab-study-for-covid-19/
https://clinicaltrials.gov/ct2/show/NCT04351152
Catalent Adds Cryogenic Capabilities at Philadelphia Clinical Supply Services Facility to Meet Growing Demand for Cell and Gene Therapy Development
SOMERSET, N.J. – April 15, 2021
https://www.catalent.com/catalent-news/catalent-adds-cryogenic-capabilities-at-philadelphia-clinical-supply-services-facility-to-meet-growing-demand-for-cell-and-gene-therapy-development/
Happy birthday Peter Hotez!!!! EAT A HOTEZ SANDWICH !!!!!!
Russian Patent VIROSOME
Methods of producing adjuvanted virosome and adjuvanted virosomes, obtained by said methods
https://patents.google.com/patent/RU2694367C2/en
An example of a virosome vaccine against the flu virus manufactured in Russia is “Grifor”, produced by Microgen (Moscow) and officially approved for medical use in the Russian Federation in 2008. “Ultrix” is another Russian-made next-generation flu vaccine, also effective against the swine flu (Shamsheva et al., 2014).
https://scfh.ru/en/papers/virosomes-new-contents-of-the-old-form/
# : 30 Dec 2020 , Fungi against Viruses and Tumors , volume 55, N2
Virosomes: new contents of the old form
Nature has created a variety of biological nanodevices and nanomachines; we can reprogram elements of these machines to solve the challenges of modern biology and medicine. Biopharmaceutics is a field where virosomes find numerous applications. Molecules of proteins, DNA, RNA and their complexes are successfully used to construct therapeutic drugs and vaccines. This is the foundation of the medicine of the future, which will be based on smart drugs that selectively target infections agents or biopolymers that define the functioning of human cells
https://scfh.ru/en/papers/virosomes-new-contents-of-the-old-form/
BCG vaccination may induce heterologous immunity and protect against Covid-19
By GlobalData Healthcare
23 Apr 2020 (Last Updated September 4th, 2020 09:03)
Baylor College of Medicine and Ain Shams University are both conducting similar trials in which the patient population consists of health workers, and the trials are under Phase IV and Phase III level of development, respectively. The study populations are split into two cohorts consisting of an experimental arm receiving the BCG vaccination and a placebo comparator arm. The primary outcome of both of these studies is focused on the incidence of Covid-19 rather than the abseentism. The Ain Shams study measures the incidence of Covid-19 over nine months, while the Baylor study measures the primary outcome through a six-month period. The Baylor study has Harvard University, Radboud University Medical Centre, and University of Texas MD Anderson Cancer Center all listed as collaborators. This trial is also notable because it is the first to exhibit international collaboration in BCG trials targeted against Covid-19.
https://www.pharmaceutical-technology.com/comment/bcg-vaccination-covid-19/